"10.1371_journal.pone.0033329","plos one","2012-03-19T00:00:00Z","Ralf Schröder; Luzheng Xue; Viktoria Konya; Lene Martini; Nora Kampitsch; Jennifer L Whistler; Trond Ulven; Akos Heinemann; Roy Pettipher; Evi Kostenis","Molecular-, Cellular- and Pharmacobiology Section, Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany; Biomedical Research Centre, NDM Experimental Medicine, University of Oxford, Oxford, United Kingdom; Institute of Experimental and Clinical Pharmacology, Medical University Graz, Graz, Austria; Ernest Gallo Clinic and Research Center, University of California San Francisco, Emeryville, California, United States of America; Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark; Oxagen Ltd, Abingdon, Oxon, United Kingdom","Conceived and designed the experiments: RS LX VK LM NK. Performed the experiments: RS LX VK LM NK. Analyzed the data: RS LX VK LM NK . Contributed reagents/materials/analysis tools: TU JLW. Wrote the paper: EK. Edited the manuscript and provided valuable comments: TU JLW. Contributed to data interpretation: AH RP. Contributed to conception and design of the study: AH RP. Edited the manuscript: AH RP TU JLW.","RP is employed by Oxagen, which is in the process of developing CRTH2 antagonists for clinical use. AH has received research funding from AstraZeneca (3000 Euro consultancy and lecture fees; 150.000 Euro research funding). All authors declare there are no other relevant declarations relating to employment, consultancy, patents, products in development or marketed products. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2012","03","Ralf Schröder","RS",10,TRUE,5,5,6,1,TRUE,TRUE,FALSE,0,NA,FALSE
